Year to date, Nuvalent’s shares have surged 42.4% compared with the industry’s 1.0% growth. During this timeframe, the stock ...

Scattered investor qualms about Nuvalent Inc.’s largely upbeat data during the European Society for Medical Oncology (ESMO) ...

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.

Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million ...

Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...

In terms of valuation, Nuvalent Inc’s market capitalization stands at $7.27 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing ...

The S&P 500 inched higher overnight as investors awaited the Federal Reserve’s highly anticipated policy meeting, where ...

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected ...

Analyst Rating Boosts Investor Confidence. Today, Stifel released a pivotal update on Nuvalent’s stock. The analyst firm maintained its “Buy” rating but raised the price tar ...